BACKGROUND: The Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cancer clinical trials research cooperative, has recently formed an Outcomes Committee to assess a comprehensive array of clinical trial endpoints and factors impacting the net effect of therapy. METHODS: To study outcomes in a consistent, comprehensive and coordinated manner, the RTOG Outcomes Committee developed a model to assess clinical, humanistic, and economic outcomes important in clinical trials. RESULTS: This paper reviews how the RTOG incorporates outcomes research into cancer clinical trials, and demonstrates utilization of the RTOG Outcomes Model to test hypotheses related to non-small-cell lung cancer (NSCLC). In this example, the clinical component of the model indicates that the addition of chemotherapy to radiotherapy (RT) improves survival but increases the risk of toxicity. The humanistic component indicates that esophagitis is the symptom impacting quality of life the greatest and may outweigh the benefits in elderly (> or =70 years) patients. The economic component of the model indicates that accounting for quality-adjusted survival, concurrent chemoRT for the treatment of NSCLC is within the range of economically acceptable recommendations. CONCLUSION: The RTOG Outcomes Model guides a comprehensive program of research that systematically measures a triad of endpoints considered important to clinical trials research.
BACKGROUND: The Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cancer clinical trials research cooperative, has recently formed an Outcomes Committee to assess a comprehensive array of clinical trial endpoints and factors impacting the net effect of therapy. METHODS: To study outcomes in a consistent, comprehensive and coordinated manner, the RTOG Outcomes Committee developed a model to assess clinical, humanistic, and economic outcomes important in clinical trials. RESULTS: This paper reviews how the RTOG incorporates outcomes research into cancer clinical trials, and demonstrates utilization of the RTOG Outcomes Model to test hypotheses related to non-small-cell lung cancer (NSCLC). In this example, the clinical component of the model indicates that the addition of chemotherapy to radiotherapy (RT) improves survival but increases the risk of toxicity. The humanistic component indicates that esophagitis is the symptom impacting quality of life the greatest and may outweigh the benefits in elderly (> or =70 years) patients. The economic component of the model indicates that accounting for quality-adjusted survival, concurrent chemoRT for the treatment of NSCLC is within the range of economically acceptable recommendations. CONCLUSION: The RTOG Outcomes Model guides a comprehensive program of research that systematically measures a triad of endpoints considered important to clinical trials research.
Authors: A Gregor; A Cull; R J Stephens; J A Kirkpatrick; J R Yarnold; D J Girling; F R Macbeth; R Stout; D Machin Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: Andrea Bezjak; Peter Dixon; Michael Brundage; Dong Tu; Michael J Palmer; Paul Blood; Clive Grafton; Catherine Lochrin; Carson Leong; Liam Mulroy; Colum Smith; James Wright; Joseph L Pater Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-01 Impact factor: 7.038
Authors: D F Cella; B Orofiamma; J C Holland; P M Silberfarb; S Tross; M Feldstein; M Perry; L H Maurer; R Comis; E J Orav Journal: Cancer Date: 1987-10-01 Impact factor: 6.860
Authors: Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley Journal: J Natl Cancer Inst Date: 2011-12-07 Impact factor: 13.506
Authors: Deborah Watkins Bruner; Andrea Barsevick; Chunqiao Tian; Marcus Randall; Robert Mannel; David E Cohn; Joel Sorosky; Nick M Spirtos Journal: Qual Life Res Date: 2006-10-11 Impact factor: 4.147
Authors: D Franceschini; F De Rose; L Cozzi; P Navarria; E Clerici; C Franzese; T Comito; A Tozzi; C Iftode; G D'Agostino; M Sorsetti Journal: Strahlenther Onkol Date: 2017-02-06 Impact factor: 3.621
Authors: Deborah Watkins Bruner; Charlene J Bryan; Neil Aaronson; C Craig Blackmore; Michael Brundage; David Cella; Patricia A Ganz; Carolyn Gotay; Pamela S Hinds; Alice B Kornblith; Benjamin Movsas; Jeff Sloan; Lari Wenzel; Giles Whalen Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: Joshua S Niedzielski; Jinzhong Yang; Zhongxing Liao; Daniel R Gomez; Francesco Stingo; Radhe Mohan; Mary K Martel; Tina M Briere; Laurence E Court Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-21 Impact factor: 7.038
Authors: Joshua S Niedzielski; Jinzhong Yang; Francesco Stingo; Mary K Martel; Radhe Mohan; Daniel R Gomez; Tina M Briere; Zhongxing Liao; Laurence E Court Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-14 Impact factor: 7.038